Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $14
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Jefferies analyst Kelly Shi maintains ImmunityBio (NASDAQ:IBRX) with a Buy and raises the price target from $12 to $14.
Jefferies analyst Kelly Shi maintains ImmunityBio (NASDAQ:IBRX) with a Buy and raises the price target from $12 to $14.